What does Rakesh Jhunjhunwala see in Jubilant Life Sciences?
Within a year, the investing legend has doubled down on his latest pharma bet
Himanshu Kakkar - May 23, 2020
How Biocon has been leading from the front | Editor's Note
Kiran Mazumdar Shaw's bold biologics bet is set to reap rewards
N Mahalakshmi - April 25, 2020
The bitter truth
In Bottle of Lies: Ranbaxy and The Dark Side of Indian Pharma, author Katherine Eban investigates the fall of Ranbaxy — a doom of its own making
September 27, 2019
New growth model
Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Kripa Mahalingam - July 26, 2019
Tricky Transition
Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs
N Mahalakshmi - July 16, 2019
Just what the doctor ordered
The Indian pharma industry has a stellar decadal run and it’s not going to change anytime soon
December 23, 2017
A new prescription
Tectonic changes in the US generic drugs market is causing huge shifts in Indian pharma’s strategies as well
Team Outlook Business - December 17, 2015